What did BioNTech and OncoC4 report at the 2026 World Conference on Lung Cancer about gotistobart in the first stage of the two-stage phase 3 Preserve-003 trial for metastatic, pretreated squamous non-small cell lung cancer without actionable genomic alterations—including its med

BioNTech and OncoC4 reported that updated, non-pivotal stage 1 data from PRESERVE-003 showed a potentially large survival advantage for gotistobart over docetaxel in previously treated metastatic squamous NSCLC. But this is not yet practice-changing proof: the randomized pivotal stage 2 must confirm the result.

What WCLC reported

• In the 87-patient stage 1 cohort, updated median overall survival was 18.5 months with gotistobart versus 10.0 months with docetaxel, with a hazard ratio of 0.56 (nominal p=0.0295)—a 44% relative reduction in the instantaneous risk of death. The earlier analysis, at 14.5 months’ median follow-up, had not yet reached median survival for gotistobart and reported HR 0.46 (95% CI 0.25–0.84; nominal p=0.0102). 18

• The patients had metastatic squamous NSCLC progressing after prior PD-(L)1 immunotherapy and platinum chemotherapy. This is a particularly difficult setting, with chemotherapy long remaining the standard and typical survival under one year, so an 18.5-month median—if reproduced—would be unusually consequential. 1

• A direct numerical comparison with Trodelvy (sacituzumab govitecan), Datroway (datopotamab deruxtecan), or Cabometyx plus Tecentriq (cabozantinib plus atezolizumab) would not be scientifically valid without a head-to-head trial: populations, histology, prior therapy, endpoints, and follow-up differ. None establishes that gotistobart is superior to those regimens. Trodelvy also has important treatment toxicity, including grade 3–4 diarrhea reported in 11% across its labeled safety population. 6

Why the result could matter

• Squamous NSCLC has fewer targeted-treatment opportunities than genomically driven nonsquamous disease, and post-immunotherapy/platinum options are limited. That makes a chemotherapy-free treatment with a robust, durable overall-survival signal potentially a major advance rather than simply another incremental option. 1

• The relevant claim is prospective: positive pivotal-stage confirmation could alter the treatment landscape for relapsed squamous NSCLC. It should not be interpreted as an established standard of care yet. 1

Mechanism and regulatory status

• Gotistobart (BNT316/ONC-392) is a pH-sensitive anti-CTLA-4 monoclonal antibody designed to selectively deplete immunosuppressive regulatory T cells in the tumor microenvironment. 1

• The pH-sensitive design allows antibody–CTLA-4 complexes to dissociate after internalization, permitting CTLA-4 recycling; the intended result is to preserve peripheral checkpoint function while enhancing anti-tumor immunity in the tumor. 1

• The FDA granted gotistobart Orphan Drug Designation for squamous NSCLC in 2025; it had also received FDA Fast Track designation in 2022 for metastatic NSCLC progressing after anti-PD-(L)1 therapy. 1

Safety caveat

• In the WCLC update, grade 3 or worse treatment-related adverse events occurred in 44.4% of gotistobart-treated patients and 48.8% of docetaxel-treated patients. 1

• Treatment-related adverse events reportedly led to discontinuation in 15.6% with gotistobart versus 4.9% with docetaxel; severe colitis was the leading grade 3-or-higher treatment-related toxicity with gotistobart. 1

• Thus, the potential survival benefit has to be weighed against clinically meaningful immune-related toxicity, particularly colitis—not simply described as a uniformly easier or safer alternative to chemotherapy. Anti-cancer immune therapies can cause immune-mediated colitis requiring treatment interruption or discontinuation. 3

What comes next

• The pivotal second stage of PRESERVE-003 is ongoing globally and is intended to confirm overall-survival benefit versus docetaxel. 1

• BioNTech has indicated an interim analysis is expected in late 2026. A positive, adequately powered result could support a substantial shift in second- or later-line treatment for relapsed squamous NSCLC; a negative or less compelling result would substantially temper the stage 1 findings. Insufficient evidence is available to predict that outcome.